Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : offers its newest HIV drug candidate to patent pool for low-cost production

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CET

Gilead Sciences is licensing its newest HIV drug candidate, bictegravir, to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income countries once it is approved.

Gilead said it will include the HIV-1 candidate in its existing agreements with generic drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan and SeQuent Scientific, as a single agent or in fixed-dose combinations with other HIV medicines, upon regulatory approval in the U.S. It also will allow the MPP to sub-license it to other generic producers in India, China and South Africa.

Competition among manufacturers has reduced the lowest price of a Gilead HIV generic therapy by 80 percent since 2006, to as low as $3.50 per patient per month. Ninety-nine percent of people taking Gileads HIV therapies in developing countries receive generic medicine, Gilead said in an announcement today.

Of course, it is the branded version in the U.S. and Europe, where drug approvals are currently pending, that Gilead is most interested in and where it will compete with GlaxoSmithKlines $1.2 billion seller Tivicay (dolutegravir). The FDA has set a Feb.12, 2018 target date for consideration.

Analysts initially believed bictegravir, if approved, was going to be a red-hot competitor to the GSK med but phase 3 data released last spring cooled those expectations somewhat. While four studies of the investigational integrase strand transfer inhibitor hit their primary endpoints by measuring up to Tivicay and other antiretroviral agents, they didnt prove that bictegravir is superior. Then in data released today, it reported the same finding at 48 weeks.

GSK, which has been aggressively building its HIV focused ViiV Healthcare, is taking another tack in its assault on market leader Gileads $10 billion-plus HIV franchise. The U.K.-based company is betting on a two-drug, dolutegravir-containing regimen that could potentially cut down on the side-effect burden of Gileads three-drug approaches, and their cost, too.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09:12a GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
01:31a GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/11 GILEAD SCIENCES : Today’s Research Reports on Stocks to Watch: Gilead Sciences a..
12/11 GILEAD SCIENCES : and Kite to Acquire Cell Design Labs
12/11 GILEAD SCIENCES : Hookipa raises EUR 50 million series C
12/11 GILEAD SCIENCES : acquires CDL for $567m
12/11 GILEAD SCIENCES : US stocks end higher on Friday on the back of strong jobs data
12/11 GILEAD : Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
12/10 GILEAD SCIENCES : acquires CDL for $567m
12/10 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
More news
News from SeekingAlpha
06:13a YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/10 GILEAD DOUBLES DOWN ON CAR-T : Updates To Thesis
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/08 GILEAD SCIENCES : Going Down When It Should Go Up
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,71%
P/E ratio 2017 9,75
P/E ratio 2018 12,72
EV / Sales 2017 4,33x
EV / Sales 2018 4,91x
Capitalization 99 094 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249
EXELIXIS, INC.80.42%7 816